Another strong contributor during the quarter was Perrigo Co. (NYSE:PRGO) which climbed over 11 percent and added 24 basis points of performance to the Fund. The generic drug maker entered into an agreement with GlaxoSmithKline PLC to acquire a portfolio of over-the-counter drugs. Perrigo has already make acquisitions in the OTC business and this deal should allow them to capture an even larger share of the significant OTC market in Europe.
From the Keeley Mid-Cap Value Fund Second Quarter 2015 Commentary.
